Talazoparib in combination with enzalutamide is now approved for treatment of patients with HRRm mCRPC. This program will review the clinical efficacy and safety for the combination.
A New Combination Treatment for Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
